Adagene, Inc. (DE:978)
NASDAQ:978
978 Stock Chart & Stats
€3.14
€0.08(4.35%)
At close: 4:00 PM EST
€3.14
€0.08(4.35%)
Day’s Range― - ―
52-Week Range€1.18 - €3.84
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€138.37M
Enterprise Value€81.20M
Total Cash (Recent Filing)€74.52M
Total Debt (Recent Filing)€6.26M
Price to Earnings (P/E)―
Beta0.15
Next Earnings
Sep 02, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding66,072,590
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.02
Price to Sales (P/S)9.30
P/FCF Ratio-4.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€7.18Price Target Upside128.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.41
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Data StrengthRobust, differentiated clinical signals in hard‑to‑treat HCC and MSS colorectal cancer indicate muzastotug may serve as a backbone combination therapy. Durable efficacy with manageable safety raises probability of a registrational path, partner interest, and long‑term commercial potential.
Strategic CollaborationsMultiple collaborations with established pharma (Incyte and others across programs) provide validation, shared development resources and alternative commercialization routes. Partnership breadth de‑risks single‑asset failure and enables milestone/revenue streams supporting sustained R&D.
Improved Funding RunwayMaterial year‑end cash and an extended runway into early 2028, plus a recent financing, give the company time to execute registrational dose‑optimization and combo trials. This reduces immediate refinancing risk and supports progress toward late‑stage value inflection points.
Bears Say
Negative Cash GenerationConsistent negative operating and free cash flow indicate the business is not self‑funding and relies on external capital. Ongoing cash burn constrains flexibility, raises dilution risk ahead of commercialization, and pressures timing of value realization for investors.
Volatile Revenue & Gross ProfitRevenues driven by lumpy collaborations and milestones produce inconsistent top‑line and gross profit swings. This unpredictability hampers long‑term planning, margin sustainability, and makes it harder to model recurring cash generation even as clinical progress continues.
Persistent Losses & Negative ROESustained operating and net losses with negative ROE show the company has yet to generate returns from invested capital. Continued unprofitability risks further equity dilution, reduces internal funding capacity and challenges long‑term shareholder value creation.
Adagene News
978 FAQ
What was Adagene, Inc.’s price range in the past 12 months?
Adagene, Inc. lowest stock price was €1.18 and its highest was €3.84 in the past 12 months.
What is Adagene, Inc.’s market cap?
Adagene, Inc.’s market cap is €138.37M.
When is Adagene, Inc.’s upcoming earnings report date?
Adagene, Inc.’s upcoming earnings report date is Sep 02, 2026 which is in 90 days.
How were Adagene, Inc.’s earnings last quarter?
Adagene, Inc. released its earnings results on Apr 01, 2026. The company reported -€0.086 earnings per share for the quarter, the consensus estimate of -€0.086 by €0.
Is Adagene, Inc. overvalued?
According to Wall Street analysts Adagene, Inc.’s price is currently Undervalued.
Does Adagene, Inc. pay dividends?
Adagene, Inc. does not currently pay dividends.
What is Adagene, Inc.’s EPS estimate?
Adagene, Inc.’s EPS estimate is -0.13.
How many shares outstanding does Adagene, Inc. have?
Adagene, Inc. has 66,072,590 shares outstanding.
What happened to Adagene, Inc.’s price movement after its last earnings report?
Adagene, Inc. reported an EPS of -€0.086 in its last earnings report, expectations of -€0.086. Following the earnings report the stock price went up 1.22%.
Which hedge fund is a major shareholder of Adagene, Inc.?
Currently, no hedge funds are holding shares in DE:978
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adagene Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€7.18 (128.61% Upside)
€7.18 (128.61% Upside)
Blogger Sentiment
Bullish
DE:978 Sentiment 70%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.58%
12-Months-Change
Fundamentals
Return on Equity
-48.20%
Trailing 12-Months
Asset Growth
-12.33%
Trailing 12-Months
Company Description
Adagene, Inc.
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
978 Stock 12 Month Forecast
Average Price Target
€7.18
▲(128.61% Upside)
Technical Analysis
Options Prices
Currently, No data available
---